Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia

Table 1

Changes in anthropometric and biochemical parameters during the study.

	Baseline	After treatment	% changes
Body weight (kg)	73.1 ± 15.5	72.5 ± 15.2	−0.7 ± 2.0	<0.001
Body fat (%)	31.2 ± 7.2	29.8 ± 7.4	−4.7 ± 8.4	<0.001
Fat mass (kg)	22.8 ± 7.5	21.6 ± 7.5	−5.4 ± 8.7	<0.001
Lean body mass (kg)	50.2 ± 11.4	50.8 ± 11.4	1.5 ± 4.3	0.02
BMI (kg/m^2)	27.5 ± 4.4	27.3 ± 4.3	−0.7 ± 2.3	<0.001
Waist circumference (cm)	92.4 ± 11.1	92.3 ± 11.7	−0.2 ± 3.9	0.633
Total cholesterol (mmol/L)	5.39 ± 1.00	4.56 ± 0.96	−14.5 ± 14.8	<0.001
HDL-C (mmol/L)	1.19 ± 0.27	1.45 ± 0.38	23.3 ± 22.7	<0.001
Triglycerides (mmol/L)	2.29 ± 1.25	1.44 ± 0.84	−31.8 ± 29.2	<0.001
LDL-C (mmol/L)	3.19 ± 0.92	2.46 ± 0.83	−19.8 ± 26.2	<0.001
Non-HDL (mmol/L)	4.20 ± 0.95	3.12 ± 0.93	−24.7 ± 18.8	<0.001
Free fatty acids (μEq/L)	481.8 ± 204.3	745.3 ± 351.5	74.5 ± 105.3	<0.001
Fasting glucose (mmol/L)	5.62 ± 1.12	6.15 ± 1.47	9.4 ± 13.1	<0.001
HbA1C (%)	6.33 ± 0.72	6.63 ± 0.87	4.8 ± 7.4	<0.001
Fasting insulin, mU/L	11.95 ± 8.54	17.34 ± 10.44	70.2 ± 91.0	<0.001
HOMA-IR	3.03 ± 2.31	4.78 ± 3.07	87.8 ± 103.9	<0.001
Adiponectin, µg/mL	10.32 ± 6.60	28.11 ± 22.4	169.3 ± 111.6	<0.001

BMI: body mass index; HbA1C: glycated haemoglobin; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: Homeostasis Model of Assessment-Insulin Resistance; LDL-C: low-density lipoprotein cholesterol.